Scott M Gordon1, Jonathan H Chung2, Martin P Playford2, Amit K Dey2, Denis Sviridov3, Fayaz Seifuddin4, Yun-Ching Chen4, Mehdi Pirooznia4, Marcus Y Chen5, Nehal N Mehta2, Alan T Remaley3. 1. Lipoprotein Metabolism Section, National Heart, Lung and Blood Institute, Bethesda, MD, USA. Electronic address: scott.gordon@uky.edu. 2. Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, Bethesda, MD, USA. 3. Lipoprotein Metabolism Section, National Heart, Lung and Blood Institute, Bethesda, MD, USA. 4. Bioinformatics and Computational Biology Core Facility, National Heart, Lung and Blood Institute, Bethesda, MD, USA. 5. Advanced Cardiovascular Imaging Laboratory, National Heart, Lung and Blood Institute, Bethesda, MD, USA.
Abstract
BACKGROUND AND AIMS: High density lipoprotein cholesterol (HDL-C) is associated with risk of cardiovascular disease (CVD); however, therapeutic manipulations of HDL-C have failed to reduce CVD events. This suggests that HDL-C and the atheroprotective capacity of HDL are not directly linked. The goal of this study was to evaluate the relationships between HDL-bound proteins and measures of atherosclerosis burden and HDL function. METHODS: The HDL proteome was analyzed using mass spectrometry in 126 human subjects, who had undergone coronary computed tomography angiography (CCTA) to quantify calcified (CB) and non-calcified (NCB) atherosclerosis burden. Partial least squares regression analysis was used to evaluate associations between HDL-bound proteins and CB, NCB, or cholesterol efflux capacity (CEC). RESULTS: Significant overlap was found among proteins associated with NCB and CEC. Proteins that were associated with NCB displayed an inverse relationship with CEC, supporting a link between this protective function of HDL and clinical plaque burden. CB was associated with a set of proteins mostly distinct from NCB and CEC. When CVD risk factors were evaluated, BMI had a stronger influence on important HDL proteins than gender, age, or HDL-C. Most HDL proteins associated with function or atherosclerosis burden were not significantly correlated with HDL-C. CONCLUSIONS: These findings indicate that the HDL proteome contains information not captured by HDL- C and, therefore, has potential for future development as a biomarker for CVD risk. Additionally, the proteome effects detected in this study may provide HDL compositional goals for evaluating new and existing HDL-modification therapies. Published by Elsevier B.V.
BACKGROUND AND AIMS: High density lipoprotein cholesterol (HDL-C) is associated with risk of cardiovascular disease (CVD); however, therapeutic manipulations of HDL-C have failed to reduce CVD events. This suggests that HDL-C and the atheroprotective capacity of HDL are not directly linked. The goal of this study was to evaluate the relationships between HDL-bound proteins and measures of atherosclerosis burden and HDL function. METHODS: The HDL proteome was analyzed using mass spectrometry in 126 human subjects, who had undergone coronary computed tomography angiography (CCTA) to quantify calcified (CB) and non-calcified (NCB) atherosclerosis burden. Partial least squares regression analysis was used to evaluate associations between HDL-bound proteins and CB, NCB, or cholesterol efflux capacity (CEC). RESULTS: Significant overlap was found among proteins associated with NCB and CEC. Proteins that were associated with NCB displayed an inverse relationship with CEC, supporting a link between this protective function of HDL and clinical plaque burden. CB was associated with a set of proteins mostly distinct from NCB and CEC. When CVD risk factors were evaluated, BMI had a stronger influence on important HDL proteins than gender, age, or HDL-C. Most HDL proteins associated with function or atherosclerosis burden were not significantly correlated with HDL-C. CONCLUSIONS: These findings indicate that the HDL proteome contains information not captured by HDL- C and, therefore, has potential for future development as a biomarker for CVD risk. Additionally, the proteome effects detected in this study may provide HDL compositional goals for evaluating new and existing HDL-modification therapies. Published by Elsevier B.V.
Entities:
Keywords:
Atherosclerosis; Cholesterol efflux; Computed tomography angiography; High density lipoprotein; Proteomics
Authors: Cinzia Parolini; Marta Marchesi; Paolo Lorenzon; Mauro Castano; Elena Balconi; Luigi Miragoli; Linda Chaabane; Alberto Morisetti; Vito Lorusso; Bradley J Martin; Charles L Bisgaier; Brian Krause; Roger S Newton; Cesare R Sirtori; Giulia Chiesa Journal: J Am Coll Cardiol Date: 2008-03-18 Impact factor: 24.094
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: H Benachour; M Zaiou; A Samara; B Herbeth; M Pfister; D Lambert; G Siest; S Visvikis-Siest Journal: Nutr Metab Cardiovasc Dis Date: 2009-04-05 Impact factor: 4.222
Authors: Baohai Shao; Giorgio Cavigiolio; Nathan Brot; Michael N Oda; Jay W Heinecke Journal: Proc Natl Acad Sci U S A Date: 2008-08-21 Impact factor: 11.205
Authors: W Sean Davidson; Anna Heink; Hannah Sexmith; Lawrence M Dolan; Scott M Gordon; James D Otvos; John T Melchior; Deborah A Elder; Jane Khoury; Esmond Geh; Amy S Shah Journal: J Lipid Res Date: 2017-07-25 Impact factor: 5.922
Authors: Kendra A Young; Janet K Snell-Bergeon; Ramachandra G Naik; John E Hokanson; David Tarullo; Peter A Gottlieb; Satish K Garg; Marian Rewers Journal: Diabetes Care Date: 2010-10-26 Impact factor: 19.112
Authors: W Sean Davidson; Amy S Shah; Hannah Sexmith; Scott M Gordon Journal: Biochim Biophys Acta Mol Cell Biol Lipids Date: 2021-11-18 Impact factor: 4.698
Authors: Scott M Gordon; Marcelo J Amar; Kianoush Jeiran; Michael Stagliano; Emma Staller; Martin P Playford; Nehal N Mehta; Tomas Vaisar; Alan T Remaley Journal: Lipids Health Dis Date: 2020-08-21 Impact factor: 3.876
Authors: Evgenia Gourgari; Junfeng Ma; Martin P Playford; Nehal N Mehta; Radoslav Goldman; Alan T Remaley; Scott M Gordon Journal: Cardiovasc Diabetol Date: 2019-03-28 Impact factor: 9.951
Authors: Maki Tsujita; Boris Vaisman; Liu Chengyu; Kasey C Vickers; Kei-Ichiro Okuhira; Sten Braesch-Andersen; Alan T Remaley Journal: FEBS Lett Date: 2020-10-20 Impact factor: 4.124
Authors: Evgenia Gourgari; Kristen J Nadeau; Laura Pyle; Martin P Playford; Junfeng Ma; Nehal N Mehta; Alan T Remaley; Scott M Gordon Journal: Endocrinol Diabetes Metab Date: 2021-05-09